Landscape of respiratory syncytial virus.
10.1097/CM9.0000000000003354
- Author:
Yuping DUAN
1
;
Zimeng LIU
2
;
Na ZANG
3
;
Bingbing CONG
4
;
Yuqing SHI
5
;
Lili XU
6
;
Mingyue JIANG
1
;
Peixin WANG
2
;
Jing ZOU
4
;
Han ZHANG
4
;
Ziheng FENG
6
;
Luzhao FENG
1
;
Lili REN
7
;
Enmei LIU
3
;
You LI
4
;
Yan ZHANG
5
;
Zhengde XIE
6
Author Information
1. School of Population Medicine and Public Health, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China.
2. National Health Commission Key Laboratory of Systems Biology of Pathogen, Christophe Mérieux Laboratory, National Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 102629, China.
3. Department of Respiratory Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing 400014, China.
4. Department of Epidemiology, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China.
5. National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Disease, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
6. Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Research Unit of Critical Infection in Children, Chinese Academy of Medical Sciences (2019RU016), Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health,Beijing 100045, China.
7. State Key Laboratory of Respiratory Health and Multimorbidity, National Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100029, China.
- Publication Type:Review
- MeSH:
Humans;
Respiratory Syncytial Virus Infections/prevention & control*;
Respiratory Syncytial Viruses/pathogenicity*;
Respiratory Syncytial Virus, Human/pathogenicity*;
Antiviral Agents/therapeutic use*
- From:
Chinese Medical Journal
2024;137(24):2953-2978
- CountryChina
- Language:English
-
Abstract:
Respiratory syncytial virus (RSV) is an enveloped, negative-sense, single-stranded RNA virus of the Orthopneumovirus genus of the Pneumoviridae family in the order Mononegavirales. RSV can cause acute upper and lower respiratory tract infections, sometimes with extrapulmonary complications. The disease burden of RSV infection is enormous, mainly affecting infants and older adults aged 75 years or above. Currently, treatment options for RSV are largely supportive. Prevention strategies remain a critical focus, with efforts centered on vaccine development and the use of prophylactic monoclonal antibodies. To date, three RSV vaccines have been approved for active immunization among individuals aged 60 years and above. For children who are not eligible for these vaccines, passive immunization is recommended. A newly approved prophylactic monoclonal antibody, Nirsevimab, which offers enhanced neutralizing activity and an extended half-life, provides exceptional protection for high-risk infants and young children. This review provides a comprehensive and detailed exploration of RSV's virology, immunology, pathogenesis, epidemiology, clinical manifestations, treatment options, and prevention strategies.
